$BDRX News
Last published 2d ago
- 2d agoBDRXBiodexa provides R&D UpdateGlobeNewswireNovember 9, 2026
- 2d agoBDRXBiodexa provides R&D UpdateGlobeNewswireNovember 9, 2026 Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruited Preparations advanced for Phase 1 trial of MTX240 in GIST Biodexa Pharmaceuticals PLC (NASDAQ:BDRX)
- 4w agoBDRXBiodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAPGlobeNewswireOctober 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock
- 1mo agoBDRXThe Longview: Fireside Chat with Biodexa CEO Stephen StampACCESS NewswireToday's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC is about the Company's lead program, eRapa in Familial Adenomatous Polyposis , a genetic disease of the lower GI tract
- 1mo agoBDRXBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsGlobeNewswireBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage
- 2mo agoBDRXInterim results for the six months ended June 30, 2026GlobeNewswireSeptember 11, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage
- 2mo agoBDRXBiodexa announces major milestone for its Serenta registrational Phase 3 trial in FAPGlobeNewswireAugust 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or
- 3mo agoBDRXResult of General MeetingGlobeNewswireJuly 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing
- 3mo agoBDRXBiodexa Initiates Support Activities for FAP Patients and Treatment Centers in FranceGlobeNewswireJuly 28, 2026 Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products
- 4mo agoBDRXResult of Annual General MeetingGlobeNewswireJune 30, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Result of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a
- 4mo agoBDRXBiodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and WarrantsGlobeNewswireJune 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa"
- 4mo agoBDRXApproval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta ProgressGlobeNewswireJune 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAPandUpdate on Serenta Progress Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a
- 4mo agoBDRXPostponement and Re-scheduling of Annual General MeetingGlobeNewswireJune 17, 2026 Biodexa Pharmaceuticals PLC Postponement and Re-scheduling of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company
- 6mo agoBDRXBiodexa issues letter to ShareholdersGlobeNewswireMay 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of
- 7mo agoBDRXBiodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial SuppliesGlobeNewswireApril 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company
- 7mo agoBDRXPreliminary Results for the Year Ended 31 December 2025GlobeNewswireMarch 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX),
- 7mo agoBDRXBiodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma GroupGlobeNewswireMarch 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage
- 8mo agoBDRXBiodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP PatientsGlobeNewswireMarch 9, 2026 Biodexa Announces Support for Life's a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage
- 8mo agoBDRXBiodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach CancerACCESS NewswireMTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors Meg Flippin, Benzinga Staff WriterCARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa
- 9mo agoBDRXBiodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GISTGlobeNewswireFebruary 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK –
- 10mo agoBDRXAppointment of Fiona Sharp to the Board as Chief Financial Officer and Company SecretaryGlobeNewswireJanuary 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical
- 10mo agoBDRXBiodexa Announces Pricing of $10 Million Public OfferingGlobeNewswireDecember 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of
- 11mo agoBDRXBiodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAPGlobeNewswireDecember 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage
- 11mo agoBDRXBiodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAPGlobeNewswireNovember 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) announced today that the University of Bonn, Germany is now actively
- 1y agoBDRXBiodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 BillionGlobeNewswireNovember 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion Biodexa
- 1y agoBDRXBiodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025GlobeNewswireOctober 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"),
- 1y agoBDRXInterim results for the six months ended June 30, 2025GlobeNewswireSeptember 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company
- 1y agoBDRXBiodexa Moves Into Phase 3 With eRapa For FAP With First Patients EnrolledACCESS NewswireOn Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / September 8, 2025 / Biodexa Pharmaceuticals PLC. , a late
- 1y agoBDRXBiodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)GlobeNewswireAugust 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa
- 1y agoBDRXADR Ratio Change EffectiveGlobeNewswireJuly 31, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical
- 1y agoBDRXHow Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable MarketACCESS NewswireCARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated, there is a near 100%
- 1y agoBDRXADR Ratio ChangeGlobeNewswireJuly 15, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline
- 1y agoBDRXBiodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)GlobeNewswireJuly 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage
- 1y agoBDRXResults of Annual General MeetingGlobeNewswireJune 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of
- 1y agoBDRXBiodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)GlobeNewswireJune 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a
- 1y agoBDRXBiodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a StudyACCESS NewswireCARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and
- 1y agoBDRXResult of General MeetingGlobeNewswireJune 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of
- 1y agoBDRXBiodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 DiabetesGlobeNewswireJune 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical
- 1y agoBDRXShareholder UpdateGlobeNewswireMay 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative
- 1y agoBDRXBiodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General MeetingGlobeNewswireMay 22, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Notice of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative
- 1y agoBDRXBiodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0MGlobeNewswireMay 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa
- 1y agoBDRXBiodexa Receives Orphan Drug Designation in Europe for eRapa in FAPGlobeNewswireMay 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019
- 1y agoBDRXResult of General MeetingGlobeNewswireMay 2, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative
- 1y agoBDRXNotice of General MeetingGlobeNewswireApril 17, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Notice of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of
- 1y agoBDRXPreliminary Results for the Year Ended 31 December 2024GlobeNewswireApril 11, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX),
- 1y agoBDRXWith Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next QuarterACCESS NewswireCARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. , a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of
- 1y agoBDRXBiodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPGlobeNewswireMarch 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3
- 1y agoBDRXBiodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAPGlobeNewswireMarch 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational
- 1y agoBDRXBiodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and UseGlobeNewswireFebruary 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous
- 1y agoBDRXBiodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025GlobeNewswireFebruary 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and